Key points
- Both names describe combinations of rituximab, chemotherapy medicines and a steroid.
- R-CHOP is commonly delivered in clinic on treatment days. DA-EPOCH-R usually includes a multi-day continuous infusion and dose adjustments between cycles.
- Radiotherapy is a separate treatment. Whether it is considered can depend on the whole first-line plan and the end-of-treatment assessment.
- Regimen choice needs specialist interpretation. A website cannot choose safely from a scan, stage or mass size alone.
What R-CHOP means
R-CHOP is an acronym. The letters stand for rituximab, cyclophosphamide, doxorubicin (historically called hydroxydaunomycin), vincristine (Oncovin) and prednisone. The National Cancer Institute lists each medicine in the combination.
Infusions are usually given during a clinic visit, while prednisone is taken by mouth for part of each cycle. Exact timing, number of cycles, supportive medicines and monitoring vary. Use the written schedule from your own unit rather than a schedule found online.
What DA-EPOCH-R means
DA-EPOCH-R contains rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin. “DA” means dose-adjusted. Doses of some medicines may change from one cycle to the next using blood-count results and treatment tolerance. The NCI definition explains the dose-adjustment principle.
Etoposide, vincristine and doxorubicin are commonly delivered as a continuous infusion over several days. Some centers use an inpatient stay; others may use an ambulatory pump. Blood tests between cycles help the team plan the next dose.
Why treatment plans differ
Current specialist guidance describes both R-CHOP and DA-EPOCH-R as first-line options used for primary mediastinal large B-cell lymphoma. It also states that the optimal first-line chemotherapy regimen has not been established definitively. See the Onkopedia DLBCL guideline section on PMBCL.
This is why treatment discussions can sound different between hospitals. Your team may consider disease findings, other health conditions, fertility plans, heart function, practical delivery and its wider approach to PET-guided radiotherapy. Asking why a plan fits your situation is appropriate. It is not a challenge to the team.
If future fertility matters to you, raise it before the first cycle whenever time allows. Your lymphoma team can explain urgency and arrange specialist advice.
Where PET/CT fits
PET/CT is used to assess lymphoma activity and treatment response. An end-of-treatment report may include a Deauville score and describe a residual mass. Those findings are interpreted together with scan timing, the treatment regimen, earlier images and your clinical picture.
A PET result does not select the next step by itself. If a report is unclear, ask what the team thinks it represents, what evidence supports that view and whether review, repeat imaging, biopsy or another discussion is planned.
Questions for your medical team
- What is the exact name of my treatment plan, and why do you recommend it for me?
- Which days are infusions, tablets, blood tests and recovery days?
- Will any part require a hospital stay or ambulatory pump?
- How will doses be adjusted, if at all?
- What side effects require an urgent call, including overnight?
- When will response be assessed, and how might PET/CT affect later decisions?
- Should fertility preservation be discussed before treatment begins?
- Who should I contact if the written schedule and what I remember do not match?
Medical sources
Claims above link to their sources. Links checked 23 July 2026.